Inactivation of the Wwox gene accelerates forestomach tumor progression in vivo

Cancer Research

Volumn 67, Issue 12, 2007, Pages 5606-5610

  Aqeilan, Rami I ^a   Hagan, John P ^a   Aqeilan, Haifa A ^a   Pichiorri, Flavia ^a   Fong, Louise Y Y ^a   Croce, Carlo M ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

N BENZYL N METHYLNITROSAMINE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; WW DOMAIN CONTAINING OXIDOREDUCTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CONTROLLED STUDY; EPITHELIUM; ESOPHAGUS TUMOR; GASTROINTESTINAL TUMOR; GENE INACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; CARCINOGENS; CELL TRANSFORMATION, NEOPLASTIC; DIMETHYLNITROSAMINE; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; GENE SILENCING; GENETIC PREDISPOSITION TO DISEASE; IMMUNOHISTOCHEMISTRY; MICE; NEOPLASMS, SQUAMOUS CELL; OXIDOREDUCTASES; STOMACH NEOPLASMS;

EID: 34250826625     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1081     Document Type: Article

References (18)

1. Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res 2000;60:2140-5.
2. Ried K, Finnis M, Hobson L, et al. Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum Mol Genet 2000;9:1651-63.
3. Glover TW. Common fragile sites. Cancer Lett 2006;232:4-12.
4. Aqeilan RI, Croce CM. WWOX in biological control and tumorigenesis. J Cell Physiol. Epub 2007 Apr 25.
5. Kuroki T, Trapasso F, Shiraishi T, et al. Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer Res 2002;62:2258-60.
6. Aqeilan RI, Kuroki T, Pekarsky Y, et al. Loss of WWOX expression in gastric carcinoma. Clin Cancer Res 2004;10:3053-8.
7. Aqeilan RI, Trapasso F, Hussain S, et al. Targeted deletion of Wwox reveals a tumor suppressor function. Proc Natl Acad Sci U S A 2007;104:3949-54.
8. Society AC. Cancer facts & figures 2007. American Cancer Society 2007:1-56.
9. Luch A. Nature and nurture - lessons from chemical carcinogenesis. Nat Rev Cancer 2005;5:113-25.
10. Zanesi N, Pekarsky Y, Croce CM. A mouse model of the fragile gene FHIT: from carcinogenesis to gene therapy and cancer prevention. Mutat Res 2005;591:103-9.
11. Magee PN. Nitrosamines and human cancer: introduction and overview. Eur J Cancer Prev 1996;5 Suppl 1:7-10.
12. Fong LY, Magee PN. Dietary zinc deficiency enhances esophageal cell proliferation and N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumor incidence in C57BL/6 mouse. Cancer Lett 1999;143:63-9.
13. Guler G, Uner A, Guler N, et al. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer 2004;100:1605-14.
14. Cintorino M, Tripod SA, Santopietro R, et al. Cytokeratin expression patterns as an indicator of tumour progression in oesophageal squamous cell carcinoma. Anticancer Res 2001;21:4195-201.
15. Fong LY, Ishii H, Nguyen VT, et al. p53 deficiency accelerates induction and progression of esophageal and forestomach tumors in zinc-deficient mice. Cancer Res 2003;63:186-95.
16. Coletta RD, Almeida OP, Vargas PA. Cytokeratins 1, 7 and 14 immunoexpression are helpful in the diagnosis of basaloid squamous carcinoma. Histopathology 2006;48:773-4.
17. O'Keefe LV, Richards RI. Common chromosomal fragile sites and cancer: focus on FRA16D. Cancer Lett 2006;232:37-47.
18. Huebner K, Croce CM. FRA3B and other common fragile sites: the weakest links. Nat Rev Cancer 2001;1:214-21.